NO20083547L - Novel spiro[imidazolidine-4,3'-indole]-2,2",5' (1'H)-triones for treatment of conditions associated with vanilloid receptor 1 - Google Patents

Novel spiro[imidazolidine-4,3'-indole]-2,2",5' (1'H)-triones for treatment of conditions associated with vanilloid receptor 1

Info

Publication number
NO20083547L
NO20083547L NO20083547A NO20083547A NO20083547L NO 20083547 L NO20083547 L NO 20083547L NO 20083547 A NO20083547 A NO 20083547A NO 20083547 A NO20083547 A NO 20083547A NO 20083547 L NO20083547 L NO 20083547L
Authority
NO
Norway
Prior art keywords
triones
imidazolidine
indole
treatment
conditions associated
Prior art date
Application number
NO20083547A
Other languages
English (en)
Inventor
Miroslaw Tomaszewski
Carmen Leung
Simon Woo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083547(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20083547L publication Critical patent/NO20083547L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Nye forbindelser av formel I, hvor R1 og R2 er uavhengig halogen eller C1-3 halogenalkyl, X er etenyl eller etynyl, eller et salt derav.
NO20083547A 2006-02-07 2008-08-14 Novel spiro[imidazolidine-4,3'-indole]-2,2",5' (1'H)-triones for treatment of conditions associated with vanilloid receptor 1 NO20083547L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77111906P 2006-02-07 2006-02-07
PCT/SE2007/000107 WO2007091947A2 (en) 2006-02-07 2007-02-06 Novel spiro[imidazolidine-4,3'-indole]-2,2',5(1'h)-triones for treatment of conditions associated with vanilloid receptor 1

Publications (1)

Publication Number Publication Date
NO20083547L true NO20083547L (no) 2008-11-05

Family

ID=38345567

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083547A NO20083547L (no) 2006-02-07 2008-08-14 Novel spiro[imidazolidine-4,3'-indole]-2,2",5' (1'H)-triones for treatment of conditions associated with vanilloid receptor 1

Country Status (21)

Country Link
US (2) US20070185179A1 (no)
EP (1) EP2013215A4 (no)
JP (1) JP2009526043A (no)
KR (1) KR20080094906A (no)
CN (1) CN101415711A (no)
AR (1) AR059265A1 (no)
AU (1) AU2007212786B2 (no)
BR (1) BRPI0707423A2 (no)
CA (1) CA2641632A1 (no)
CL (1) CL2009000523A1 (no)
IL (1) IL192890A0 (no)
NO (1) NO20083547L (no)
NZ (1) NZ571070A (no)
RU (1) RU2421457C2 (no)
SA (1) SA07280027B1 (no)
SG (1) SG169387A1 (no)
TW (1) TW200801011A (no)
UA (1) UA93226C2 (no)
UY (1) UY30132A1 (no)
WO (1) WO2007091947A2 (no)
ZA (1) ZA200806407B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6050238B2 (ja) * 2011-10-19 2016-12-21 興和株式会社 新規なスピロインドリン化合物、及びそれを含有する医薬
TWI586668B (zh) * 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
CN108409746B (zh) * 2018-05-15 2021-08-24 中山大学 一种含吡咯或吲哚并氮杂环烷结构的手性氧代螺环吲哚类化合物及其消旋体和制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU532110B2 (en) * 1979-11-13 1983-09-15 Ici Ltd. Spiro(imidazolidine-4,3:-indoline)-2,2:5-trione derivatives
ZA806623B (en) * 1979-11-13 1981-12-30 Ici Ltd Substituted indoline-2-one derivatives
IE52879B1 (en) * 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
GB8331194D0 (en) 1982-12-20 1983-12-29 Ici Plc Chemical process
US4611062A (en) * 1984-03-26 1986-09-09 Imperial Chemical Industries Plc Process for resolving certain spiro compounds
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
TR200200118T2 (tr) * 1999-07-21 2002-12-23 Astrazeneca Ab Yeni bileşimler
US7248802B2 (en) 2002-11-27 2007-07-24 Nokia Corporation Distribution of a synchronization signal in an optical communication system
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
EP1632477B1 (en) 2003-06-12 2017-03-01 Astellas Pharma Inc. Benzamide derivative or salt thereof
GB0326633D0 (en) * 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
JP2008508190A (ja) 2004-07-19 2008-03-21 ノボ ノルディスク アクティーゼルスカブ 肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害
CN101415713A (zh) * 2006-02-07 2009-04-22 阿斯利康(瑞典)有限公司 用于治疗香草素受体1相关病症的新螺[咪唑烷-4,3’-吲哚]-2,2’,5(1’h)-三酮

Also Published As

Publication number Publication date
RU2008131905A (ru) 2010-03-20
CN101415711A (zh) 2009-04-22
AU2007212786B2 (en) 2011-06-02
ZA200806407B (en) 2009-04-29
UA93226C2 (en) 2011-01-25
SA07280027B1 (ar) 2010-11-22
WO2007091947A2 (en) 2007-08-16
AR059265A1 (es) 2008-03-19
RU2421457C2 (ru) 2011-06-20
WO2007091947A8 (en) 2008-08-07
KR20080094906A (ko) 2008-10-27
IL192890A0 (en) 2009-02-11
CA2641632A1 (en) 2007-08-16
AU2007212786A1 (en) 2007-08-16
TW200801011A (en) 2008-01-01
US20070185179A1 (en) 2007-08-09
EP2013215A4 (en) 2010-09-08
AU2007212786A8 (en) 2010-05-06
SG169387A1 (en) 2011-03-30
BRPI0707423A2 (pt) 2011-05-03
UY30132A1 (es) 2009-07-17
WO2007091947A3 (en) 2007-10-04
US7868181B2 (en) 2011-01-11
US20090137650A1 (en) 2009-05-28
EP2013215A2 (en) 2009-01-14
NZ571070A (en) 2011-07-29
CL2009000523A1 (es) 2009-07-17
JP2009526043A (ja) 2009-07-16

Similar Documents

Publication Publication Date Title
EP2279184B1 (en) Indole modulators of the alpha-7 nicotinic acetylcholine receptor
CO5700742A2 (es) Moduladores del receptor de quimioquina ccr5
EA039885B1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
DE602005023343D1 (de) Pyrimidinderivate als gpcr-agonisten
CN106928247A (zh) 螺羟吲哚化合物及其作为治疗剂的用途
NO20080871L (no) N-(Heteroaryl)-1-heteroarylalkyl-1 H-indol-2-karboksamidderivater, fremstilling og terapeutisk anvendelse derav
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
WO2008094909A2 (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
MX2009010909A (es) Derivados de ftalazino y su uso como medicamento para tratar el cancer.
NO20075406L (no) Pyrimidindionerivater som prokineticin-2-reseprorantagonister
MX2011013294A (es) Antagonistas de la trayectoria de hedgehog y aplicaciones terapeuticas de los mismos.
MY148504A (en) Compounds which have activity at m? receptor and their uses in medicine
WO2008155670A3 (en) Arylamide pyrimidone compounds
EP4736860A2 (en) Polycyclic compounds for inhibiting rna helicase dhx33 and use thereof
WO2008155669A3 (en) Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
WO2009115486A1 (en) Triazole amide derivatives for use in therapy
MA32947B1 (fr) Piperidines substitues par aroylamino et heteroaroylamino comme inhibiteurs de glyt-1
CN113166119A (zh) 取代芳基化合物及其制备方法和用途
TW202012401A (zh) 縮環內醯胺衍生物
ATE468118T1 (de) Bis-1,2,3,4-tetrahydroisochinolinderivate und ihre verwendung als pharmazeutika
GB0501964D0 (en) Chemical compounds
JP2022547200A (ja) 三環系構造を有する芳香複素環式化合物、およびその調製方法と適用
CN110054622A (zh) 噁二唑类衍生物、其制备方法及其在医药上的应用
WO2007091947A8 (en) Novel spiro[imidazolidine-4,3'-indole]-2,2',5(1'h)-triones for treatment of conditions associated with vanilloid receptor 1
BRPI0406747A (pt) Derivados de benzoxazol e seu uso como ligandos de receptor de adenosina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application